Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma Epstein-Barr virus DNA for the prediction of treatment response and disease progression in non-keratinizing differentiated nasopharyngeal carcinoma

20 May 2025

Abstract excerpt

PURPOSE: To explore the failure patterns, outcomes, and treatment response of differentiated non-keratinizing nasopharyngeal carcinoma (DNKC) and to further investigate the role of plasma Epstein-Barr virus (EBV)-DNA in follow-up monitoring, prognostic prediction, and assessment of treatment efficacy in DNKC. METHODS: We retrospectively collected data from patients diagnosed with DNKC from January 2015 to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Head and Neck Cancer Studies
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40394615
DOI: 10.1186/s13027-025-00661-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma Epstein-Barr virus DNA for the prediction of treatment response and disease progression in non-keratinizing differentiated nasopharyngeal carcinomaPMID 40394615Read ↗

Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapySemantic proximity Read ↗

The Clinical Utility of Plasma Epstein–Barr Virus DNA Assays in Nasopharyngeal CarcinomaSemantic proximity Read ↗

Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome expression could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti–programmed cell death 1 monotherapySemantic proximity Read ↗

Spontaneous remission of residual post‐therapy plasma Epstein–Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large‐scale, big‐data intelligence platform‐based analysisSemantic proximity Read ↗

Nasopharyngeal carcinoma at the virology precision oncology nexus: decoding molecular alterations for early intervention and therapeutic innovationSemantic proximity Read ↗

Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinomaSemantic proximity Read ↗

Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinomaSemantic proximity Read ↗

The Dynamic Change in Plasma Epstein–Barr Virus DNA Load over a Long-Term Follow-Up Period Predicts Prognosis in Nasopharyngeal CarcinomaSemantic proximity Read ↗

Nasopharyngeal Carcinoma at the Virology Precision Oncology Nexus: Decoding Molecular Alterations for Early Intervention and Therapeutic Innovation.Semantic proximity Read ↗

Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive populationSemantic proximity Read ↗

Systematic comparison of plasma EBV DNA, anti‐EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinomaSemantic proximity Read ↗

Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein–Barr virus DNA in post-treatment plasmaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.